Seeking Alpha

Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to...

Jazz Pharmaceuticals (JAZZ) is down 2.1% premarket, adding to the losses seen yesterday due to an FDA warning letter related to its Xyrem drug. However, Jefferies and Piper have come to Jazz's defense, with each noting that the warning merely involves the company's monitoring procedures, rather than any production issues.
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs